1
|
Bennacef I, Rubins D, Riffel K, Williams M, Posavec DJ, Holahan MA, Purcell ML, Haley HD, Wolf M, Stachel SJ, Lubbers LS, Wesolowski GA, Duong LT, Hamill TG, Evelhoch JL, Hostetler ED. Preclinical evaluation of [ 11 C]L-235 as a radioligand for Positron Emission Tomography cathepsin K imaging in bone. J Labelled Comp Radiopharm 2020; 64:159-167. [PMID: 33226657 DOI: 10.1002/jlcr.3896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/23/2020] [Accepted: 07/30/2020] [Indexed: 11/06/2022]
Abstract
The cathepsin K (CatK) enzyme is abundantly expressed in osteoclasts, and CatK inhibitors have been developed for the treatment of osteoporosis. In our effort to support discovery and clinical evaluations of a CatK inhibitor, we sought to discover a radioligand to determine target engagement of the enzyme by therapeutic candidates using positron emission tomography (PET). L-235, a potent and selective CatK inhibitor, was labeled with carbon-11. PET imaging studies recording baseline distribution of [11 C]L-235, and chase and blocking studies using the selective CatK inhibitor MK-0674 were performed in juvenile and adult nonhuman primates (NHP) and ovariectomized rabbits. Retention of the PET tracer in regions expected to be osteoclast-rich compared with osteoclast-poor regions was examined. Increased retention of the radioligand was observed in osteoclast-rich regions of juvenile rabbits and NHP but not in the adult monkey or adult ovariectomized rabbit. Target engagement of CatK was observed in blocking studies with MK-0674, and the radioligand retention was shown to be sensitive to the level of MK-0674 exposure. [11 C]L-235 can assess target engagement of CatK in bone only in juvenile animals. [11 C]L-235 may be a useful tool for guiding the discovery of CatK inhibitors.
Collapse
Affiliation(s)
- Idriss Bennacef
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Daniel Rubins
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Kerry Riffel
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Mangay Williams
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Diane J Posavec
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Marie A Holahan
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Mona L Purcell
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Hyking D Haley
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Mary Wolf
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | | | - Laura S Lubbers
- In Vitro Pharmacology, Merck & Co., Inc., Kenilworth, NJ, USA
| | | | - Le T Duong
- Bone Biology, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Terence G Hamill
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Jeffrey L Evelhoch
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Eric D Hostetler
- Translational Biomarkers-Imaging, Merck & Co., Inc., Kenilworth, NJ, USA
| |
Collapse
|
2
|
Zheng MQ, Lin SF, Holden D, Naganawa M, Ropchan JR, Najafzaden S, Kapinos M, Tabriz M, Carson RE, Hamill TG, Huang Y. Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK-6577 in baboons. Synapse 2015; 70:112-20. [PMID: 26671330 DOI: 10.1002/syn.21879] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 12/02/2015] [Accepted: 12/11/2015] [Indexed: 01/24/2023]
Abstract
Glycine transporter type-1 (GlyT1) has been proposed as a target for drug development for schizophrenia. PET imaging with a GlyT1 specific radiotracer will allow for the measurement of target occupancy of GlyT1 inhibitors, and for in vivo investigation of GlyT1 alterations in schizophrenia. We conducted a comparative evaluation of two GlyT1 radiotracers, [(11) C]GSK931145, and [(18) F]MK-6577, in baboons. Two baboons were imaged with [(11) C]GSK931145 and [(18) F]MK-6577. Blocking studies with GSK931145 (0.3 or 0.2 mg/kg) were conducted to determine the level of tracer specific binding. [(11) C]GSK931145 and [(18) F]MK-6577 were synthesized in good yield and high specific activity. Moderately fast metabolism was observed for both tracers, with ∼ 30% of parent at 30 min post-injection. In the brain, both radiotracers showed good uptake and distribution profiles consistent with regional GlyT1 densities. [(18) F]MK-6577 displayed higher uptake and faster kinetics than [(11) C]GSK931145. Time activity curves were well described by the two-tissue compartment model. Regional volume of distribution (VT ) values were higher for [(18) F]MK-6577 than [(11) C]GSK931145. Pretreatment with GSK931145 reduced tracer uptake to a homogeneous level throughout the brain, indicating in vivo binding specificity and lack of a reference region for both radiotracers. Linear regression analysis of VT estimates between tracers indicated higher specific binding for [(18) F]MK-6577 than [(11) C]GSK931145, consistent with higher regional binding potential (BPND ) values of [(18) F]MK-6577 calculated using VT from the baseline scans and non-displaceable distribution volume (VND ) derived from blocking studies. [(18) F]MK-6577 appears to be a superior radiotracer with higher brain uptake, faster kinetics, and higher specific binding signals than [(11) C]GSK931145.
Collapse
Affiliation(s)
- Ming-Qiang Zheng
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Shu-Fei Lin
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Daniel Holden
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Mika Naganawa
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Jim R Ropchan
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Soheila Najafzaden
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Michael Kapinos
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Mike Tabriz
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Richard E Carson
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| | - Terence G Hamill
- Discovery Imaging, Merck Research Laboratories, West Point, Pennsylvania
| | - Yiyun Huang
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, PET Center, New Haven, Connecticut
| |
Collapse
|
3
|
Joshi AD, Sanabria-Bohórquez SM, Bormans G, Koole M, De Hoon J, Van Hecken A, Depre M, De Lepeleire I, Van Laere K, Sur C, Hamill TG. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse 2014; 69:33-40. [PMID: 25196464 DOI: 10.1002/syn.21782] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 07/06/2014] [Accepted: 07/26/2014] [Indexed: 01/05/2023]
Abstract
Decreased glutamatergic neurotransmission is hypothesized to be involved in the pathophysiology of schizophrenia. Inhibition of glycine transporter Type-1 (GlyT1) reuptake is expected to increase the glutamatergic neurotransmission and may serve as treatment for cognitive and negative symptoms of schizophrenia. In this article, we present human data from a novel GlyT1 PET tracer, [(18) F]MK-6577. In the process of developing a GlyT1 inhibitor therapeutic, a PET tracer can assist in determining the dose with a high probability of sufficiently testing the mechanism of action. This article reports the human PET studies with [(18) F]MK-6577 for measuring GlyT1 receptor availability at baseline in normal human subjects and occupancy with a GlyT1 inhibitor, MK-2637. Studies were also performed to measure radiation burden and the baseline test-retest (T-RT) variability of the tracer. The effective dose from sequential whole-body dosimetry scans in three male subjects was estimated to be 24.5 ± 2.9 µSV/MBq (mean ± SD). The time-activity curves from T-RT scans modeled satisfactorily using a two tissue compartmental model. The tracer uptake was highest in the pons (VT = 6.7 ± 0.9, BPND = 4.1 ± 0.43) and lowest in the cortex (VT = 2.1 ± 0.5, BPND = 0.60 ± 0.23). VT T-RT variability measured in three subjects was <12% on average. The occupancy scans performed in a cohort of 15 subjects indicated absence of a reference region. The in vivo potency (Occ50 ) of MK-2637 was determined using two methods: A: Lassen plot with a population input function (Occ50 = 106 nM, SE = 20 nM) and B: pseudo reference tissue model using cortex as the pseudo reference region (Occ50 = 141 nM, SE = 21 nM).
Collapse
|
4
|
Van Laere KJ, Sanabria-Bohórquez SM, Mozley DP, Burns DH, Hamill TG, Van Hecken A, De Lepeleire I, Koole M, Bormans G, de Hoon J, Depré M, Cerchio K, Plalcza J, Han L, Renger J, Hargreaves RJ, Iannone R. (11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists. J Nucl Med 2013; 55:65-72. [PMID: 24263088 DOI: 10.2967/jnumed.113.122515] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
UNLABELLED The histamine 3 (H3) receptor is a presynaptic autoreceptor in the central nervous system that regulates the synthesis and release of histamine and modulates the release of other major neurotransmitters. H3 receptor inverse agonists (IAs) may be efficacious in the treatment of various central nervous system disorders, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Alzheimer disease, ethanol addiction, and obesity. METHODS Using PET and a novel high-affinity and selective radioligand (11)C-MK-8278, we studied the tracer biodistribution, quantification, and brain H3 receptor occupancy (RO) of MK-0249 and MK-3134, 2 potential IA drugs targeting cerebral H3 receptors, in 6 healthy male subjects (age, 19-40 y). The relationship among H3 IA dose, time on target, and peripheral pharmacokinetics was further investigated in 15 healthy male volunteers (age, 18-40 y) with up to 3 PET scans and 3 subjects per dose level. RESULTS The mean effective dose for (11)C-MK-8278 was 5.4 ± 1.1 μSv/MBq. Human brain kinetics showed rapid high uptake and fast washout. Binding potential values can be assessed using the pons as a reference region, with a test-retest repeatability of 7%. Drug RO data showed low interindividual variability per dose (mean RO SD, 2.1%), and a targeted 90% RO can be reached for both IAs at clinically feasible doses. CONCLUSION (11)C-MK-8278 is a useful novel PET radioligand for determination of human cerebral H3 receptor binding and allows highly reproducible in vivo brain occupancy of H3-targeting drugs, hereby enabling the evaluation of novel compounds in early development to select doses and schedules.
Collapse
Affiliation(s)
- Koenraad J Van Laere
- Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Liu P, Hamill TG, Chioda M, Chobanian H, Fung S, Guo Y, Chang L, Bakshi R, Hong Q, Dellureficio J, Lin LS, Abbadie C, Alexander J, Jin H, Mandala S, Shiao LL, Li W, Sanabria S, Williams D, Zeng Z, Hajdu R, Jochnowitz N, Rosenbach M, Karanam B, Madeira M, Salituro G, Powell J, Xu L, Terebetski JL, Leone JF, Miller P, Cook J, Holahan M, Joshi A, O’Malley S, Purcell M, Posavec D, Chen TB, Riffel K, Williams M, Hargreaves R, Sullivan KA, Nargund RP, DeVita RJ. Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase. ACS Med Chem Lett 2013; 4:509-13. [PMID: 24900701 DOI: 10.1021/ml4000996] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2013] [Accepted: 04/20/2013] [Indexed: 11/29/2022] Open
Abstract
We report herein the discovery of a fatty acid amide hydrolase (FAAH) positron emission tomography (PET) tracer. Starting from a pyrazole lead, medicinal chemistry efforts directed toward reducing lipophilicity led to the synthesis of a series of imidazole analogues. Compound 6 was chosen for further profiling due to its appropriate physical chemical properties and excellent FAAH inhibition potency across species. [(11)C]-6 (MK-3168) exhibited good brain uptake and FAAH-specific signal in rhesus monkeys and is a suitable PET tracer for imaging FAAH in the brain.
Collapse
Affiliation(s)
| | - Terence G. Hamill
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Wenping Li
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Sandra Sanabria
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - David Williams
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Zhizhen Zeng
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | | | | | | | | | | | | | | | | | | | | | - Patricia Miller
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Jacquelynn Cook
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Marie Holahan
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Aniket Joshi
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Stacey O’Malley
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Mona Purcell
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Diane Posavec
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Tsing-Bau Chen
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Kerry Riffel
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Mangay Williams
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | - Richard Hargreaves
- Department of Imaging Research, Merck Research Laboratories, West Point, Pennsylvania
19486, United States
| | | | | | | |
Collapse
|
6
|
Wong DF, Waterhouse R, Kuwabara H, Kim J, Brašić JR, Chamroonrat W, Hamill TG, Mozley PD, Dannals RF, Hamill TG, Mozley PD. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med 2013; 54:388-96. [PMID: 23404089 PMCID: PMC9911749 DOI: 10.2967/jnumed.112.107995] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Identification of safe and valid PET radioligands for metabotropic glutamate receptor, type 5 (mGluR5), is essential to measure changes in brain mGluR5 in neuropsychiatric disorders, to confirm central mGluR5 occupancy of drug candidates, and to guide dose selection for obtaining an optimum therapeutic window. Here we present the results of a first-in-human study assessing the safety and effectiveness of a novel PET radiopharmaceutical, (18)F-3-fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ((18)F-FPEB), for quantifying regional brain concentrations of mGluR5. METHODS Quantification of whole-body biokinetics was conducted in 6 healthy adults (3 men and 3 women). The radiation safety profile was estimated with OLINDA/EXM software. Subsequently, pairs of dynamic brain scans were obtained for 11 healthy men to identify optimal methods for derivation of regional distribution volume and binding potential and to determine the repeatability of measurement. RESULTS The whole-body effective radiation dose was approximately 17 μSv/MBq (62 mrem/mCi), with the gallbladder receiving the highest dose of 190 μSv/MBq. In brain studies, time-activity curves showed high accumulation in the insula/caudate nucleus, moderate uptake in the thalamus, and the lowest concentration in the cerebellum/pons. The plasma reference graphical analysis method appeared optimal for (18)F-FPEB; it showed acceptable test-retest variability of nondisplaceable binding potential (<10%) and identified the highest nondisplaceable binding potential values (from ∼0.5 in the globus pallidus to ∼3.5 in the insula) for target regions. Safety assessments revealed no clinically meaningful changes in vital signs, electrocardiogram, or laboratory values. CONCLUSION (18)F-FPEB is safe and well tolerated, and its regional cerebral distribution is consistent with previous reports in the literature for metabotropic glutamate receptors. The repeatability of measurement suggests that (18)F-FPEB is suitable for quantifying mGluR5 in humans.
Collapse
Affiliation(s)
- Dean F. Wong
- Department of Psychiatry, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA,Department of Neuroscience, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA,Department of Environmental Health Sciences, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA,The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA,Honorary Professor of Neuroscience and Pharmacology, University of Copenhagen, Denmark,Corresponding author: Dean F. Wong, MD, PhD, Telephone Number: 410-955-8433, Fax: 410-955-0696, , Postal Address: 601 N. Caroline St., JHOC Room 3245, Johns Hopkins Medical Institutions, Baltimore, MD 21287-0807, USA
| | | | - Hiroto Kuwabara
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA
| | - Jongho Kim
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA
| | - James R. Brašić
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA
| | - Wichana Chamroonrat
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., JHOC, Baltimore, MD 21287-0807, USA
| | | | | | | | | | | |
Collapse
|
7
|
Hamill TG, Eng W, Jennings A, Lewis R, Thomas S, Wood S, Street L, Wisnoski D, Wolkenberg S, Lindsley C, Sanabria-Bohórquez SM, Patel S, Riffel K, Ryan C, Cook J, Sur C, Burns HD, Hargreaves R. The synthesis and preclinical evaluation in rhesus monkey of [¹⁸F]MK-6577 and [¹¹C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse 2011; 65:261-70. [PMID: 20687108 DOI: 10.1002/syn.20842] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Two positron emission tomography radiotracers for the glycine transporter 1 (GlyT1) are reported here. Each radiotracer is a propylsulfonamide-containing benzamide and was labeled with either carbon-11 or fluorine-18. [¹¹C]CMPyPB was synthesized by the alkylation of a 3-hydroxypyridine precursor using [¹¹C]MeI, and [¹⁸F]MK-6577 was synthesized by a nucleophilic aromatic substitution reaction using a 2-chloropyridine precursor. Each tracer shows good uptake into rhesus monkey brain with the expected distribution of highest uptake in the pons, thalamus, and cerebellum and lower uptake in the striatum and gray matter of the frontal cortex. In vivo blockade and chase studies of [¹⁸F]MK-6577 showed a large specific signal and reversible binding. In vitro autoradiographic studies with [¹⁸F]MK-6577 showed a large specific signal in both rhesus monkey and human brain slices and a distribution consistent with the in vivo results and those reported in the literature. In vivo metabolism studies in rhesus monkeys demonstrated that only more-polar metabolites are formed for each tracer. Of these two tracers, [¹⁸F]MK-6577 was more extensively characterized and is a promising clinical positron emission tomography tracer for imaging GlyT1 and for measuring GlyT1 occupancy of therapeutic compounds.
Collapse
Affiliation(s)
- Terence G Hamill
- Discovery Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sanabria-Bohórquez SM, Joshi AD, Holahan M, Daneker L, Riffel K, Williams M, Li W, Cook JJ, Hamill TG. Quantification of the glycine transporter 1 in rhesus monkey brain using [18F]MK-6577 and a model-based input function. Neuroimage 2011; 59:2589-99. [PMID: 21930214 DOI: 10.1016/j.neuroimage.2011.08.080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2011] [Revised: 08/23/2011] [Accepted: 08/25/2011] [Indexed: 10/17/2022] Open
Abstract
BACKGROUND Glycine transporter 1 (GlyT1) inhibitors have emerged as potential treatments for schizophrenia due to their potentiation of NMDA receptor activity by modulating the local concentrations of the NMDA co-agonist glycine. [18F]MK-6577 is a potent and selective GlyT1 inhibitor PET tracer. Although differences in ligand kinetics can be expected between non-human primates and humans, the tracer pre-clinical evaluation can provide valuable information supporting protocol design and quantification in the clinical space. The main objective of this work was to evaluate the in vivo kinetics of [18F]MK-6577 in rhesus monkey brain. Additionally, a method for estimating the tracer input function from the tracer brain tissue kinetics and venous sampling was validated. This technique was applied for determination of the dose-occupancy relationship of a GlyT1 inhibitor in monkey brain. METHODS Compartmental and Logan graphical analysis were utilized for quantification of the [18F]MK-6577 binding using the measured tracer arterial input function. The stability of the tracer volume of distribution relative to scan length was assessed. The proposed model-based input function method takes advantage of the agreement between the tracer concentration in arterial and venous plasma from ~5 min. The approach estimates the initial peak of the input curve by adding a gamma like function term to the measured venous curve. The parameters of the model function were estimated by simultaneously fitting several brain time activity curves to a compartmental model. RESULTS Good agreement was found between the model-based and the measured arterial plasma curve and the corresponding distribution volumes. The Logan analysis was the preferred method of analysis providing reliable and stable volume of distribution and occupancy results using a 90 and possibly 60 min scan length. CONCLUSION The model-based input function method and Logan analysis are well suited for quantification of [18F]MK-6577 binding and GlyT1 occupancy in monkey brain.
Collapse
|
9
|
Blackaby WP, Lewis RT, Thomson JL, Jennings ASR, Goodacre SC, Street LJ, MacLeod AM, Pike A, Wood S, Thomas S, Brown TA, Smith A, Pillai G, Almond S, Guscott MR, Burns HD, Eng W, Ryan C, Cook J, Hamill TG. Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett 2010; 1:350-4. [PMID: 24900218 DOI: 10.1021/ml1001085] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2010] [Accepted: 06/21/2010] [Indexed: 11/30/2022] Open
Abstract
Amalgamation of the structure-activity relationship of two series of GlyT1 inhibitors developed at Merck led to the discovery of a clinical candidate, compound 16 (DCCCyB), which demonstrated excellent in vivo occupancy of GlyT1 transporters in rhesus monkey as determined by displacement of a PET tracer ligand.
Collapse
Affiliation(s)
- Wesley P. Blackaby
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Richard T. Lewis
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Joanne L. Thomson
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Andrew S. R. Jennings
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Simon C. Goodacre
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Leslie J. Street
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Angus M. MacLeod
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Andrew Pike
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Suzanne Wood
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Steve Thomas
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Terry A. Brown
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Alison Smith
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Gopalan Pillai
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Sarah Almond
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - Martin R. Guscott
- Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom
| | - H. Donald Burns
- Research Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Waisi Eng
- Research Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Christine Ryan
- Research Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Jacquelynn Cook
- Research Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Terence G. Hamill
- Research Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486
| |
Collapse
|
10
|
Li W, Thompson W, Fisher T, Wai JS, Hazuda D, Burns HD, Hamill TG. Radiosynthesis of the HIV integrase inhibitor [18F]MK-0518 (Isentress). J Labelled Comp Radiopharm 2010. [DOI: 10.1002/jlcr.1778] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Sanabria-Bohórquez SM, Hamill TG, Goffin K, De Lepeleire I, Bormans G, Burns HD, Van Laere K. Kinetic analysis of the cannabinoid-1 receptor PET tracer [18F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging 2009; 37:920-33. [DOI: 10.1007/s00259-009-1340-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2009] [Accepted: 11/13/2009] [Indexed: 12/20/2022]
|
12
|
Hamill TG, Sato N, Jitsuoka M, Tokita S, Sanabria S, Eng W, Ryan C, Krause S, Takenaga N, Patel S, Zeng Z, Williams D, Sur C, Hargreaves R, Burns HD. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009; 63:1122-32. [DOI: 10.1002/syn.20689] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
13
|
Hamill TG, Sato N, Jitsuoka M, Tokita S, Krause S, Ryan C, Gantert L, Sleph H, Zeng Z, Miller P, Patel S, Riffel K, Sanabria S, Eng W, Chen T, Renger J, Doran S, Garson S, Iannone R, Hargreaves R, Burns H. Histamine H3 inverse agonist PET tracers labelled with carbon-11 or fluorine-18. Neuroimage 2008. [DOI: 10.1016/j.neuroimage.2008.04.196] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
14
|
Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol 2007; 34:1009-17. [PMID: 17998106 DOI: 10.1016/j.nucmedbio.2007.07.009] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Revised: 07/10/2007] [Accepted: 07/12/2007] [Indexed: 11/19/2022]
Abstract
Binding of [18F]3-fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]F-PEB) was evaluated in membranes and tissue sections prepared from rat, rhesus and human brain. Saturation equilibrium binding experiments with frozen brain cortex and caudate-putamen membranes of young adult rhesus and human and with cortex and striatum from rat yielded data indicative of specific high-affinity binding (KD=0.1-0.15 nM, n> or =3) to a saturable site previously shown to be metabotropic glutamate receptor 5 (mGluR5; Patel S, Ndubizu O, Hamill T, Chaudhary A, Burns HD, Hargreaves RJ, Gibson RE. Screening cascade and development of potential positron emission tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol Imaging Biol 2005;7:314-323). High-affinity binding of [18F]F-PEB was also detected in cerebellum membranes from rat, rhesus and human. The density of binding sites (Bmax) measured using [18F]F-PEB followed the rank order cortex approximately caudate-putamen/striatum>cerebellum for all three species, with the cerebellum Bmax being significantly lower than that observed in the other regions. Receptor autoradiography studies in tissue sections confirmed that the regional distribution of [18F]F-PEB in mammalian central nervous system is consistent with that of mGluR5 and that a small but specific mGluR5 signal is observed in rhesus and human cerebellum. A small and quantifiable specific signal could also be observed in rat cerebellum using this radiotracer. Immunohistochemical analysis in brain sections revealed a rank order of staining in rhesus and human brain of cortex approximately caudate-putamen>cerebellum. Rat brain immunohistochemistry followed the same rank order, although the staining in the cerebellum was significantly lower. Using a "no-wash" wipe assay, the development of a specific signal within 20 min of incubation of tissue brain sections (>60% in the cortex and striatum; 36-49% in the cerebellum) from all three species confirmed previous in vivo data from rat and rhesus monkey that [18F]PEB is likely to provide a useful in vivo signal using positron emission tomography (PET). This study provides the first quantitative demonstration and direct comparison of a PET tracer candidate identifying mGluR5 binding sites in mammalian cerebellum, which subsequently raises questions in terms of using the cerebellum as a null tissue in PET imaging studies in the laboratory and the clinic.
Collapse
Affiliation(s)
- Shil Patel
- Department of Research Imaging, Merck Research Laboratories, West Point, PA 19486, USA.
| | | | | | | | | | | |
Collapse
|
15
|
Liu P, Lin LS, Hamill TG, Jewell JP, Lanza TJ, Gibson RE, Krause SM, Ryan C, Eng W, Sanabria S, Tong X, Wang J, Levorse DA, Owens KA, Fong TM, Shen CP, Lao J, Kumar S, Yin W, Payack JF, Springfield SA, Hargreaves R, Burns HD, Goulet MT, Hagmann WK. Discovery of N-{(1S,2S)-2-(3-Cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a Cannabinoid-1 Receptor Positron Emission Tomography Tracer Suitable for Clinical Use. J Med Chem 2007; 50:3427-30. [PMID: 17608398 DOI: 10.1021/jm070131b] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The discovery of a structurally distinct cannabinoid-1 receptor (CB1R) positron emission tomography tracer is described. Starting from an acyclic amide CB1R inverse agonist (1) as the lead compound, an efficient route to introduce 18F to the molecule was developed. Further optimization focused on reducing the lipophilicity and increasing the CB1R affinity. These efforts led to the identification of [18F]-16 that exhibited good brain uptake and an excellent signal-to-noise ratio in rhesus monkeys.
Collapse
|
16
|
Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 2007; 104:9800-5. [PMID: 17535893 PMCID: PMC1877985 DOI: 10.1073/pnas.0703472104] [Citation(s) in RCA: 264] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
[(18)F]MK-9470 is a selective, high-affinity, inverse agonist (human IC(50), 0.7 nM) for the cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging. Autoradiographic studies in rhesus monkey brain showed that [(18)F]MK-9470 binding is aligned with the reported distribution of CB1 receptors with high specific binding in the cerebral cortex, cerebellum, caudate/putamen, globus pallidus, substantia nigra, and hippocampus. Positron emission tomography (PET) imaging studies in rhesus monkeys showed high brain uptake and a distribution pattern generally consistent with that seen in the autoradiographic studies. Uptake was blocked by pretreatment with a potent CB1 inverse agonist, MK-0364. The ratio of total to nonspecific binding in putamen was 4-5:1, indicative of a strong specific signal that was confirmed to be reversible via displacement studies with MK-0364. Baseline PET imaging studies in human research subject demonstrated behavior of [(18)F]MK-9470 very similar to that seen in monkeys, with very good test-retest variability (7%). Proof of concept studies in healthy young male human subjects showed that MK-0364, given orally, produced a dose-related reduction in [(18)F]MK-9470 binding reflecting CB1R receptor occupancy by the drug. Thus, [(18)F]MK-9470 has the potential to be a valuable, noninvasive research tool for the in vivo study of CB1R biology and pharmacology in a variety of neuropsychiatric disorders in humans. In addition, it allows demonstration of target engagement and noninvasive dose-occupancy studies to aid in dose selection for clinical trials of CB1R inverse agonists.
Collapse
Affiliation(s)
- H Donald Burns
- Imaging Research, Merck Research Laboratories, West Point, PA 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ludeman SM, Shulman-Roskes EM, Gamcsik MP, Hamill TG, Chang YH, Koo KI, Colvin OM. Synthesis of 15N and 17O labelled phosphoramide mustards. J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.2580330410] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
18
|
Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, Cosford NDP, Roppe J, Kamenecka T, Patel S, Gibson RE, Sanabria S, Riffel K, Eng W, King C, Yang X, Green MD, O'Malley SS, Hargreaves R, Burns HD. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005; 56:205-16. [PMID: 15803497 DOI: 10.1002/syn.20147] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Three metabotropic glutamate receptor subtype 5 (mGluR5) PET tracers have been labeled with either carbon-11 or fluorine-18 and their in vitro and in vivo behavior in rhesus monkey has been characterized. Each of these tracers share the common features of high affinity for mGluR5 (0.08-0.23 nM vs. rat mGluR5) and moderate lipophilicity (log P 2.8-3.4). Compound 1b was synthesized using a Suzuki or Stille coupling reaction with [11C]MeI. Compounds 2b and 3b were synthesized by a SNAr reaction using a 3-chlorobenzonitrile precursor. Autoradiographic studies in rhesus monkey brain slices using 2b and 3b showed specific binding in cortex, caudate, putamen, amygdala, hippocampus, most thalamic nuclei, and lower binding in the cerebellum. PET imaging studies in monkey showed that all three tracers readily enter the brain and provide an mGluR5-specific signal in all gray matter regions, including the cerebellum. The specific signal observed in the cerebellum was confirmed by the autoradiographic studies and saturation binding experiments that showed tracer binding in the cerebellum of rhesus monkeys. In vitro metabolism studies using the unlabeled compounds showed that 1a, 2a, and 3a are metabolized slower by human liver microsomes than by monkey liver microsomes. In vivo metabolism studies showed 3b to be long-lived in rhesus plasma with only one other more polar metabolite observed.
Collapse
Affiliation(s)
- Terence G Hamill
- Merck Research Laboratories, Imaging Research Department, West Point, PA 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Hamill TG, McCauley JA, Burns HD. The synthesis of a benzamidine-containing NR2B-selective NMDA receptor ligand labelled with tritium or fluorine-18. J Labelled Comp Radiopharm 2005. [DOI: 10.1002/jlcr.871] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Solin O, Eskola O, Hamill TG, Bergman J, Lehikoinen P, Grönroos T, Forsback S, Haaparanta M, Viljanen T, Ryan C, Gibson R, Kieczykowski G, Hietala J, Hargreaves R, Burns HD. Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK receptor quantitation: ([F]SPA-RQ). Mol Imaging Biol 2004; 6:373-84. [PMID: 15564148 DOI: 10.1016/j.mibio.2004.08.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
PURPOSE To develop and characterize a radiolabelled Substance-P antagonist useful for quantitation of neurokinin-1 receptors in the brain via PET imaging. PROCEDURE [18F]SPA-RQ (Substance-P antagonist - receptor quantifier) was synthesized in good yield and high specific activity by alkylation of a BOC protected phenolate anion using [18F]bromofluoromethane. Removal of the BOC protecting group with trifluoroacetic acid gave [18F]SPA-RQ. RESULTS SPA-RQ has high affinity for human, rhesus monkey and guinea pig NK1 receptors (h-IC50=67 pM) and has a log P value of 1.8. Biodistribution studies in guinea pig showed that this tracer penetrates the blood-brain barrier and selectively labels NK1 receptors in the striatum and cortex. CONCLUSION [18F]SPA-RQ is a potent, high affinity Substance-P antagonist that can be conveniently labeled with high specific activity using [18F]fluoromethylbromide. This tracer is a useful tool for noninvasive imaging of central NK1 receptors.
Collapse
|
21
|
|
22
|
Posner GH, Asirvatham E, Hamill TG, Webb KS. Three-different-component [1+2+n]-annulation reactions: ionic and radical cyclizations. J Org Chem 2002. [DOI: 10.1021/jo00294a029] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Posner GH, Hamill TG. An asymmetric total synthesis of fragrant spiro[4.5]decane sesquiterpene (-)-.beta.-vetivone via an enantiomerically pure vinylic sulfoxide. J Org Chem 2002. [DOI: 10.1021/jo00261a008] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
|
25
|
|
26
|
Duggan ME, Duong LT, Fisher JE, Hamill TG, Hoffman WF, Huff JR, Ihle NC, Leu CT, Nagy RM, Perkins JJ, Rodan SB, Wesolowski G, Whitman DB, Zartman AE, Rodan GA, Hartman GD. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. J Med Chem 2000; 43:3736-45. [PMID: 11020288 DOI: 10.1021/jm000133v] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7, 8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.
Collapse
Affiliation(s)
- M E Duggan
- Departments of Medicinal Chemistry, Bone Biology and Osteoporosis Research, and Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Non-Invasive Radiotracer Imaging (NIRI) uses either short-lived positron-emitting isotopes, such as 11C and 18F, for Positron Emis ion Tomography (PET) or single photon emitting nuclides, e.g., 123I, which provide images using planar imaging or Single-Photon Emission Computed Tomography (SPECT). These high-resolution imaging modalities provide anatomical distribution and localization of radiolabeled drugs, which can be used to generate real time receptor occupancy and off-rate studies in humans. This can be accomplished by either isotopically labeling a potential new drug (usually with 11C), or indirectly by studying how the unlabelled drug inhibits specific radioligand binding in vivo. Competitive blockade studies can be accomplished using a radiolabeled analogue which binds to the site of interest, rather than a radiolabeled version of the potential drug. Imaging, particularly PET imaging, can be used to demonstrate the effect of a drug through a biochemical marker of processes such as glucose metabolism or blood flow. NIRI as a development tool in the pharmaceutical industry is gaining increased acceptance as its unique ability to provide such critical information in human subjects is recognized. This section will review recent examples that illustrate the utility of NIRI, principally PET, in drug development, and the potential of imaging advances in the development of cancer drugs and gene therapy. Finally, we provide a brief overview of the design of new radiotracers for novel targets.
Collapse
Affiliation(s)
- R E Gibson
- Department of Pharmacology, Merck Research Labs, West Point, PA. 19486, USA
| | | | | | | | | | | |
Collapse
|
28
|
|
29
|
Burns HD, Hamill TG, Eng WS, Francis B, Fioravanti C, Gibson RE. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Curr Opin Chem Biol 1999; 3:388-94. [PMID: 10419855 DOI: 10.1016/s1367-5931(99)80059-3] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Improved communication and cooperation between research-driven drug companies and academic positron emission tomography (PET) centers, coupled with improvements in PET camera resolution, the availability of small animal PET cameras and a growing list of neuroreceptor-specific PET tracers, have all contributed to a substantial increase in the use and value of PET as a tool in central nervous system drug discovery and development.
Collapse
Affiliation(s)
- H D Burns
- Department of Pharmacology, Merck Research Laboratories, WP44C-2, Sumneytown Pike, West Point, PA 19438, USA.
| | | | | | | | | | | |
Collapse
|
30
|
Hamill TG, Hutchinson JH, Brashear KM, Hartman GD. Non-peptide fibrinogen receptor antagonists. 41. The synthesis of [3H]L-756,568. J Labelled Comp Radiopharm 1999. [DOI: 10.1002/(sici)1099-1344(199906)42:6<605::aid-jlcr222>3.0.co;2-l] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
31
|
|
32
|
Szabo Z, Kao PF, Burns HD, Gibson RE, Hamill TG, Ravert HT, Kim SE, Mathews WB, Musachio JL, Scheffel U, Dannals RF. Investigation of angiotensin II/AT1 receptors with carbon-11-L-159,884: a selective AT1 antagonist. J Nucl Med 1998; 39:1209-13. [PMID: 9669396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
UNLABELLED Antagonists of the angiotensin II AT1 receptor subtype have been recently introduced for treatment of arterial hypertension and for pharmacological studies of these receptors. The purpose of this work was to label such an antagonist with 11C and test the applicability of the radioligand for PET studies. METHODS The potent and selective nonpeptide AT1 antagonist L-159,884 was labeled with 11C and injected intravenously into six dogs. Renal accumulation and kinetics of the radioligand were imaged with PET at baseline and after receptor blockade with 1 mg/kg MK-996. Time-activity curves were derived from the renal cortex and were analyzed by the Gjedde-Patlak plot to obtain the influx rate constant of the radioligand. RESULTS There was selective radioligand binding in the kidneys, mainly located in the cortex. Within the time interval between 95 and 115 min postinjection, the radioactivity retained in the kidneys was 109 +/- 27 and 42 +/- 4 nCi/ml/mCi of the injected dose for the control and inhibition studies, respectively. The influx rate constant of the radioligand decreased from a baseline of 0.0298 +/- 0.0156 to a post-MK-996 value of 0.0098 +/- 0.0052. CONCLUSION These results demonstrate distinct binding of 11C-L-159,884 in the renal cortex with a specific binding component suitable for quantitative PET imaging of angiotensin II/AT1 receptors.
Collapse
Affiliation(s)
- Z Szabo
- Division of Nuclear Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hamill TG, Hutchinson JH, Hartman GD, Burns HD. Non-peptide fibrinogen receptor antagonists. 31. The synthesis of [3H]L-767,685 and [3H]L-767,679. J Labelled Comp Radiopharm 1998. [DOI: 10.1002/(sici)1099-1344(199807)41:7<677::aid-jlcr118>3.0.co;2-l] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
34
|
Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther 1998; 285:1317-26. [PMID: 9618439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A critical function of fibrinogen in hemostasis and thrombosis is to mediate platelet aggregation by binding selectively to an activated form of glycoprotein (GP) IIb/IIIa. Although numerous peptide and nonpeptide fibrinogen receptor antagonists have been described, their binding selectivity for resting and activated platelets has not been explored. Therefore, dissociation constants of GP IIb/IIIa antagonists for two biochemically separated forms of purified GP IIb/IIIa and for resting and activated platelets were determined by competitive displacement of the dansyl fluorophore containing GP IIb/IIIa antagonist L-736,622. Also, coating either form of the purified GP IIb/IIIa onto yttrium silicate scintillation proximity assay fluomicrospheres produced an activated form of the receptor, whose binding affinity for GP IIb/IIIa antagonists was measured conveniently by competition with the arginine-glycine-aspartic acid (RGD) containing heptapeptide [125I]L-692,884. In addition, direct binding measurements with radiolabeled GP IIb/IIIa antagonists also were performed on resting and activated platelets. We identified two classes of compounds. One class binds to both forms of GP IIb/IIIa, as well as resting and activated platelets, with similar Kd values (e.g., L-736,622 and Echistatin). The other class of compounds binds with much higher affinity to the activated form of GP IIb/IIIa (purified or on platelets) as compared with the resting form (e.g., L-734,217, MK-852, tirofiban and L-692,884). Selective antagonists, like L-734,217 (KdActivated = 5 nM and KdResting = 620 nM), can effectively inhibit ex vivo platelet aggregation at concentrations of drug that produce low levels of occupancy of the circulating platelet receptors. The potential clinical advantages of selective versus nonselective GP IIb/IIIa antagonists remain to be explored in clinical trials.
Collapse
Affiliation(s)
- R A Bednar
- Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Hamill TG, Askew BC, Hartman GD, Claremon DA, McIntyre CJ, Burns HD. Non-peptide fibrinogen receptor antagonists. 21. The synthesis of [3H]L-738,167. J Labelled Comp Radiopharm 1998. [DOI: 10.1002/(sici)1099-1344(199804)41:4<273::aid-jlcr76>3.0.co;2-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
36
|
Abstract
The rates of the non-enzymatic conjugation of the substituted aniline mustards, melphalan, chlorambucil and p-(N,N-bis(2-chloroethyl))toluidine with glutathione and thiosulfate were determined using nuclear magnetic resonance spectroscopy. Using this method, the disappearance of drug and the formation of both the mono-thioether and bis-thioether conjugates can be monitored directly. For glutathione conjugation, the rate constants for the formation of the first and second aziridinium intermediates were similar. With thiosulfate conjugation, the rate constant for the formation of the first aziridinium intermediate is greater than the rate constant for the formation of the second aziridinium. This demonstrates that the type of nucleophile has a significant influence on the overall alkylating activity of these bifunctional mustards. The bisthioether adduct formed from the reaction between p-(N,N-bis([2-13C]-2-chloroethyl))toluidine and glutathione and thiosulfate can be identified and scrambling of the 13C label in the product provides strong evidence that the alkylation must occur through an aziridinium intermediate.
Collapse
Affiliation(s)
- M P Gamcsik
- Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | | | | |
Collapse
|
37
|
Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics. Drug Metab Dispos 1997; 25:355-61. [PMID: 9172954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
L-738,167 is a potent and long-acting fibrinogen receptor antagonist and may be useful for treatment of chronic thrombotic occlusive disorders. The purposes of this study were to characterize the metabolism and disposition of L-738,167, and to investigate factors affecting its pharmacokinetic behaviors in dogs, one of the animal models used in pharmacological and toxicological studies. In vitro and in vivo experiments indicated that L-738,167 was not metabolized to any appreciable extent in dogs. Biliary excretion was found to be the major route (approximately 75%) of drug elimination. Following 1 and 3 micrograms/kg iv doses, blood pharmacokinetics of L-738,167 were linear. Total blood clearance (CLB) was much lower than hepatic blood flow, and the apparent volume of distribution at steady-state (Vdss,B) was comparable with blood volume. Blood pharmacokinetics in the dose range of 3-250 micrograms/kg were dose-dependent; both CLB and Vdss,B for L-738,167 increased markedly with increasing doses. However, the terminal half-life (t1/2) was dose-independent, with a mean value of approximately 4 days. L-738,167 was found to bind negligibly to dog plasma proteins. Determinations of whole blood (WB), platelet-rich plasma, and platelet-poor plasma concentrations after several intravenous doses of [3H]L-738,167 revealed significant concentration-dependent binding of the compound to platelets. Kinetic analysis of the platelet binding indicated that L-738,167 was bound to dog platelets with high affinity (apparent Kd approximately 1 nM platelet-poor plasma concentration) and relatively low capacity (approximately 70 nM WB concentration). Findings are consistent with the binding kinetics of L-738,167 to glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, supporting that GP IIb/IIIa was the primary binding component on the platelets. It was concluded that the dose-dependent pharmacokinetics of L-738,167 were the consequence of the concentration-dependent drug-platelet binding. Due to this extensive platelet binding, L-738,167, when given in therapeutic doses or lower, resided primarily in the vascular compartment-the site of pharmacological action. At doses exceeding the receptor binding capacity, the excess amount or the unbound drug was eliminated rapidly. In all cases, the equally long t1/2 of L-738,167 was also a consequence of the high-affinity binding to platelets, in good agreement with its prolonged pharmacodynamic profile.
Collapse
Affiliation(s)
- T Prueksaritanont
- Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
| | | | | | | | | | | |
Collapse
|
38
|
Hamill TG, Burns HD, Dannals RF, Mathews WB, Musachio JL, Ravert HT, Naylor EM. Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging. Appl Radiat Isot 1996; 47:211-8. [PMID: 8852629 DOI: 10.1016/0969-8043(95)00273-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
[11C]L-159,884 ([11C] N-[[4'[(2-ethyl-5,7-dimethyl-3H- imidazo[4,5-b]pyridin-3-yl) methyl] [1,1'-biphenyl]-2-yl] sulfonyl]-4-methoxybenzamide) and [11C]L-162,574 ([11C] N-[[4'[2-ethyl-5,7- dimethyl-3H-imidazo[4,5-b] pyridin-3-yl)methyl] [1,1'-biphenyl]-2-yl]sulfonyl]-3- methoxybenzamide), both potent and selective ligands for the AT1 receptor, were prepared by C-11 methylation of the corresponding desmethyl phenolic precursors. The radiotracers were purified by semi-preparative reverse-phase HPLC. Non-decay corrected radiochemical yields were 5 and 3% for L-159,884 and L-162,574 respectively, and the average specific activity was 2979 mCi/mumol at end-of-synthesis (EOS). The average time of synthesis was 18 min.
Collapse
Affiliation(s)
- T G Hamill
- Department of Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA
| | | | | | | | | | | | | |
Collapse
|
39
|
Kim SE, Scheffel U, Szabo Z, Burns HD, Gibson RE, Ravert HT, Mathews WB, Hamill TG, Dannals RF. In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist. J Nucl Med 1996; 37:307-11. [PMID: 8667067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
UNLABELLED Angiotensin II (ANG II) initiates a variety of physiological effects by binding to high affinity receptors. Two ANG II receptor subtypes, AT1 and AT2, have recently been identified. This study was undertaken to evaluate [11C]L-159,884, an AT1 subtype selective nonpeptide antagonist, as a potential PET tracer. METHODS Carbon-11-L-159,884 was prepared by alkylation of the nor precursor with [11C]methyliodide and was studied for its in vivo binding characteristics, biodistribution and kinetics in mice. The effects of PD-123319, an AT2-selective ANGII antagonist, as well as those of alpha- and beta-adrenergic drugs on [11C]L-159,884 binding were investigated also. RESULTS Administration of the AT1 antagonists resulted in dose-dependent inhibition of [11C]L-159,884 binding in the kidneys, the organ with the highest density of AT1 receptors. Inhibition was also observed in the lungs and the heart. Adrenergic drugs did not influence [11C]L-159,884 binding to AT1 receptors. Kinetic studies showed rapid tracer uptake in the liver, kidneys, lungs and heart. Excretion of the radioactivity occurred primarily through the intestinal tract (> 20% in 90 min), with less than 8% excreted through the urine. CONCLUSION The results suggest that [11C]L-159,884 binds in vivo to AT1 receptors in mouse kidneys, lungs and heart. This radiotracer appears to be a promising candidate for studying ANG II receptors in vivo by PET.
Collapse
Affiliation(s)
- S E Kim
- Division of Nuclear Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Many cancer cells are resistant to chemotherapeutic treatment with mechlorethamine and other alkylating agents. These drug-resistant cells often show an increase in the intracellular concentration of glutathione and an increase in the activity of glutathione-S-transferase when compared to the sensitive cells. Both of these components are thought to be involved with inactivation of the drug either through conjugation with glutathione or by hydrolysis. NMR spectroscopy was used to monitor the nonenzymatic conjugation of mechlorethamine with glutathione. Several intermediates along the pathway to the doubly glutathione substituted mustard, including both mustard-aziridinium adducts, can be observed. The assignment of the 1H NMR spectrum of these adducts are presented. At 30 degrees C, pH 7.0, no hydrolyzed mustard was detectable. With the use of 13C-labeled mustard, the conjugation reaction can be shown to proceed through an aziridinium intermediate rather than by direct nucleophilic substitution.
Collapse
Affiliation(s)
- M P Gamcsik
- Department of Radiology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21205
| | | | | |
Collapse
|
41
|
Posner GH, Weitzberg M, Hamill TG, Asirvatham E, Cun-heng H, Clardy J. Asymmetric michael additions of ester enolates to enantiomerically pure vinylic sulfoxides. Tetrahedron 1986. [DOI: 10.1016/s0040-4020(01)90581-2] [Citation(s) in RCA: 60] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Abstract
Abstract
The European standardized method for measuring porphobilinogen synthase (PBGS, EC 4.2.1.24) activity in peripheral erythrocytes is widely used in epidemiological studies of low-level Pb absorption. We have modified it to include activation with dithiothreitol (DTT). In children with concentrations of Pb in whole blood ranging from 0.29 to 1.93 mumol/L, we found the following statistically significant correlations (r): blood Pb vs nonactivated PBGS activity = -0.773 (p less than 0.005); blood Pb vs DTT-activated PBGS activity = -0.265 (p less than 0.005); blood Pb vs the ratio of DTT-activated/nonactivated PBGS activity = +0.818 (p less than 0.005). At a DTT-activated/nonactivated PBGS activity ratio of 1, which indicates no Pb-dependent inhibition of PBGS, a corresponding blood Pb concentration of 0.24 mumol/L (50 micrograms/L) would be predicted. In individuals with hematological disorders, the DTT-activated/nonactivated ratio better predicted blood concentration of Pb than did the nonactivated PBGS activity, and largely compensated for the high variability in PBGS activity. We also describe techniques to minimize contamination by Zn and Pb and to stabilize enzyme activity during collection, transport, storage, and analysis of samples.
Collapse
|
43
|
Chisolm JJ, Thomas DJ, Hamill TG. Erythrocyte porphobilinogen synthase activity as an indicator of lead exposure in children. Clin Chem 1985; 31:601-5. [PMID: 3978795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The European standardized method for measuring porphobilinogen synthase (PBGS, EC 4.2.1.24) activity in peripheral erythrocytes is widely used in epidemiological studies of low-level Pb absorption. We have modified it to include activation with dithiothreitol (DTT). In children with concentrations of Pb in whole blood ranging from 0.29 to 1.93 mumol/L, we found the following statistically significant correlations (r): blood Pb vs nonactivated PBGS activity = -0.773 (p less than 0.005); blood Pb vs DTT-activated PBGS activity = -0.265 (p less than 0.005); blood Pb vs the ratio of DTT-activated/nonactivated PBGS activity = +0.818 (p less than 0.005). At a DTT-activated/nonactivated PBGS activity ratio of 1, which indicates no Pb-dependent inhibition of PBGS, a corresponding blood Pb concentration of 0.24 mumol/L (50 micrograms/L) would be predicted. In individuals with hematological disorders, the DTT-activated/nonactivated ratio better predicted blood concentration of Pb than did the nonactivated PBGS activity, and largely compensated for the high variability in PBGS activity. We also describe techniques to minimize contamination by Zn and Pb and to stabilize enzyme activity during collection, transport, storage, and analysis of samples.
Collapse
|